Jacob Naparstek

Jacob Naparstek

Auto-generated profile, based on publicly available information

Jacob Naparstek

Parker Institute for Cancer Immunotherapy Center at UCLA, Los Angeles, California

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2022 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
SLSarah M. Larson
Sarah M. Larson
CWChristopher M. Walthers
Christopher M. Walthers
BJBrenda Ji
Brenda Ji
SGSanaz N. Ghafouri
Sanaz N. Ghafouri
JNJacob Naparstek
Jacob Naparstek
YCYvonne Y. Chen
Yvonne Y. Chen
To address antigen escape and loss of T-cell functionality, we report a phase I clinical trial (NCT04007029) evaluating autologous naive and memory T (TN/MEM) cells engineered to express a bispecific anti-CD19/CD20 chimeric antigen receptor (CAR; CART19/20) for patients with relapsed/refractory non-Hodgkin lymphoma (NHL), with safety as the primary endpoint. Ten patients were treated with 36 × 106 to 165 × 106 CART19/20 cells. No patient experienced neurotoxicity of any grade or over grade 1 cytokine release syndrome. One case of dose-limiting toxicity (persistent cytopenia) was observed. Nine of 10 patients achieved objective response [90% overall response rate (ORR)], with seven achieving complete remission [70% complete responses (CR) rate]. One patient relapsed after 18 months in CR but returned to CR after receiving a second dose of CART19/20 cells. Median progression-free survival was 18 months and median overall survival was not reached with a 17-month median follow-up. In conclusion, CART19/20 TN/MEM cells are safe and effective in patients with relapsed/refractory NHL, with durable responses achieved at low dosage levels. Significance: Autologous CD19/CD20 bispecific CAR-T cell therapy generated from TN/MEM cells for patients with NHL is safe (no neurotoxicity, maximum grade 1 cytokine release syndrome) and demonstrates strong efficacy (90% ORR, 70% CR rate) in a first-in-human, phase I dose-escalation trial. This article is highlighted in the In This Issue feature, p. 517

4 April 2023
Verified
Other
Open access
SLSarah M. Larson
Sarah M. Larson
CWChristopher M. Walthers
Christopher M. Walthers
BJBrenda Ji
Brenda Ji
SGSanaz N. Ghafouri
Sanaz N. Ghafouri
JNJacob Naparstek
Jacob Naparstek
YCYvonne Y. Chen
Yvonne Y. Chen
Patient 009 exhibited elevated cytokine, C-reactive protein, and ferritin levels prior to and after CART19/20 cell infusion. (A) Serum levels of various cytokines measured by Luminex multiplex assay. (B) C-reactive protein (CRP) levels for Patient 009 (left-most) and all patients (second from left). Peak and median CRP levels are shown in box-and-whisker plots. (C) Ferritin levels for Patient 009 (left-most) and all patients (second from left). Peak and median ferritin levels are shown in box-and-whisker plots.

4 April 2023
Verified
Other
Open access
SLSarah M. Larson
Sarah M. Larson
CWChristopher M. Walthers
Christopher M. Walthers
BJBrenda Ji
Brenda Ji
SGSanaz N. Ghafouri
Sanaz N. Ghafouri
JNJacob Naparstek
Jacob Naparstek
YCYvonne Y. Chen
Yvonne Y. Chen
CART19/20 cell product characteristics. (A) % CD4+ among total T cells and CAR-expressing T cells. (B) Comparison of T-cell subtype frequency among CD4+ vs. CD8+ T cells in cryopreserved CART19/20 cell products. Te/exh: effector/exhausted T cells, CD45RA+/CD45RO–/CD62L–; Tem: effector-memory T cells, CD45RA–/CD45RO+/CD62L–; Tcm: central-memory T cells: CD45RA–/CD45RO+/CD62L+; naïve: CD45RA+/CD45RO–/CD62L+. (C) Phenotype of leukopak content prior to cell isolation. (D) Phenotype of cells obtained after isolation. (E) CD14 and CD25 expression patterns among CD62L+ cells in patient leukopak content prior to cell isolation.

4 April 2023
Verified
Other
Open access
SLSarah M. Larson
Sarah M. Larson
CWChristopher M. Walthers
Christopher M. Walthers
BJBrenda Ji
Brenda Ji
SGSanaz N. Ghafouri
Sanaz N. Ghafouri
JNJacob Naparstek
Jacob Naparstek
YCYvonne Y. Chen
Yvonne Y. Chen
Representativeness of study participants


4 April 2023
Verified
Other
Open access
SLSarah M. Larson
Sarah M. Larson
CWChristopher M. Walthers
Christopher M. Walthers
BJBrenda Ji
Brenda Ji
SGSanaz N. Ghafouri
Sanaz N. Ghafouri
JNJacob Naparstek
Jacob Naparstek
YCYvonne Y. Chen
Yvonne Y. Chen
Representativeness of study participants